FDA Expands Approval of Setmelanotide for Acquired Hypothalamic Obesity

The Food and Drug Administration (FDA) has expanded the approved indication for setmelanotide (Imcivree, Rhythm Pharmaceuticals) to include the treatment of children and adults with acquired hypothalamic obesity, Rhythm Pharmaceuticals announced on March 20, 2026. This marks the first FDA-approved therapy specifically for this condition.

What is Setmelanotide?

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist. It was previously approved for obesity caused by Bardet-Biedl syndrome, pro-opiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, and leptin receptor (LEPR) deficiency. The expanded approval now covers acquired hypothalamic obesity, which occurs when patients experience accelerated and sustained weight gain due to injury or dysfunction of the hypothalamus.

TRANSCEND Trial Results

The approval is based on data from the phase 3 TRANSCEND trial. Results showed that patients treated with setmelanotide experienced an 18.4% greater decrease in body mass index (BMI) compared to those receiving a placebo at one year (P < .0001). The drug was generally well-tolerated, with the most commonly reported adverse events including skin hyperpigmentation, nausea, vomiting, and headache.

Expert Commentary

“Setmelanotide has shown effectiveness in targeting the underlying biology of acquired hypothalamic obesity,” said Ashley Shoemaker, MD, MSCI, associate professor of pediatrics, pediatric endocrinology at Vanderbilt Health, in a press release. “Patients treated with setmelanotide experienced meaningful reductions in BMI and hunger, demonstrating the therapy’s ability to deliver clinically significant outcomes in both children and adult patients. Acquired hypothalamic obesity is a severe disease that requires early and proactive management. With the availability of Imcivree, physicians can offer a targeted therapy.”

Implications and Future Directions

The FDA’s expanded approval of setmelanotide provides a much-needed treatment option for individuals struggling with acquired hypothalamic obesity. Early and proactive management of this condition is crucial, and Imcivree offers a targeted approach to address the underlying biological mechanisms driving weight gain in these patients. Further research will continue to refine the use of setmelanotide and explore its potential in other obesity-related conditions.